Novel ADC Boosts Survival in Pretreated Endometrial Cancer

1 source1 article First seen 13 hours ago Updated 13 hours ago United States Truth score 38

Save Like Comments Compare coverage

Summary

(MedPage Today) -- Results from the TroFuse-005 trial presented at the annual European Society for Medical Oncology congress showed that the investigational antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) significantly improved...

Description from Medpagetoday.

Who is covering this

Medpagetoday Center Factuality: Mostly factual US 13 hours ago
Novel ADC Boosts Survival in Pretreated Endometrial Cancer
(MedPage Today) -- Results from the TroFuse-005 trial presented at the annual European Society for Medical Oncology congress showed that the investigational antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) significantly improved...

Comments

Comments need JavaScript.

Truth score

38/100Weakly supported

Independent outlets: 1
Source reliability: 65/100
Sides of the spectrum covering it: 1/3
Propaganda risk: 0/100

How well the story is corroborated by independent, reliable outlets across the spectrum. Not a fact-check of each claim. How the truth score works

Coverage by lean

Centre 100%100%

Left: 0
Centre: 1
Right: 0
Not rated: 0

How lean is counted

Source quality

Average reliability: 65/100 (Mostly factual)
Low-credibility outlets: 0%
State media: 0%
Opinion pieces: 0%

Where ratings come from

Where the coverage comes from

United States1

In this story

European Society Medical Oncology

Filter the stories

Sources Ratings and details

Novel ADC Boosts Survival in Pretreated Endometrial Cancer

Summary

Who is covering this

Comments

Summary

Who is covering this

Comments

Related stories

Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial

Enfortumab Vedotin-Based Treatment Solidified for Muscle-Invasive Bladder Cancer